{Reference Type}: Case Reports
{Title}: A rare clinical presentation of COVID 19: opsoclonus-myoclonus ataxia syndrome.
{Author}: Altunsoy A;Kemirtlek N;Araz H;Dirik EB;Akıncı E;
{Journal}: J Infect Dev Ctries
{Volume}: 18
{Issue}: 2
{Year}: 2024 Feb 29
{Factor}: 2.552
{DOI}: 10.3855/jidc.17927
{Abstract}: <B>BACKGROUND: </B>Coronavirus disease 2019 (COVID-19) can have symptoms like many neurological diseases, and one of the rare forms of these presentations is opsoclonus-myoclonus ataxia syndrome (OMAS). The pathogenesis of OMAS in adults has not been clearly elucidated and OMAS can be fatal.<BR><B>METHODS: </B>We present a 71-year-old male patient who was admitted to the emergency department with complaints of involuntary tremor-like movements in his hands, feet and mouth, and speech impediment for three days, and was followed up with COVID-19. The patient was diagnosed with OMAS and clonazepam treatment was started. He died three days later due to respiratory arrest. Our case is the first case diagnosed with COVID-19-associated OMAS in Turkey.<BR><B>CONCLUSIONS: </B>OMAS has no definitive treatment. Early diagnosis and initiation of corticosteroids and intravenous immunoglobulin (IVIG) therapy, if necessary, can be life-saving. In COVID-19 patients with unexplained clinical findings, awareness of different and rare diseases and a multidisciplinary approach has vital importance.